Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | +0.57% | +1.43% | -51.37% |
May. 08 | Top Premarket Gainers | MT |
May. 08 | Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue | MT |
Financials (USD)
Sales 2024 * | 59.87M | Sales 2025 * | 11.16M | Capitalization | 151M |
---|---|---|---|---|---|
Net income 2024 * | -101M | Net income 2025 * | -168M | EV / Sales 2024 * | -1.54 x |
Net cash position 2024 * | 243M | Net cash position 2025 * | 249M | EV / Sales 2025 * | -8.84 x |
P/E ratio 2024 * |
-1.57
x | P/E ratio 2025 * |
-1.09
x | Employees | 179 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Repare Therapeutics Inc.
1 day | +0.57% | ||
1 week | +1.43% | ||
Current month | +14.52% | ||
1 month | +10.59% | ||
3 months | -46.46% | ||
6 months | -29.28% | ||
Current year | -51.37% |
Managers | Title | Age | Since |
---|---|---|---|
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Steve Forte
DFI | Director of Finance/CFO | 45 | 19-09-30 |
Michael Zinda
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 19-02-28 |
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Ann Rhoads
BRD | Director/Board Member | 58 | 20-06-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.33% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 3.55 | +0.57% | 219,390 |
24-05-16 | 3.53 | -1.12% | 114,854 |
24-05-15 | 3.57 | -3.25% | 182,946 |
24-05-14 | 3.69 | -0.27% | 254,884 |
24-05-13 | 3.7 | +5.71% | 301,631 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.37% | 151M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B |
- Stock Market
- Equities
- RPTX Stock